SCHEMBL2277797

SCHEMBL2277797

CC(C)(O)CNN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL22532157 0.97
SCHEMBL28149648 0.78
SCHEMBL23097377 0.73
SCHEMBL1817888 0.72 ALDH1A1 (0.44)
SCHEMBL519987 0.72
SCHEMBL23898978 0.69
SCHEMBL469067 0.69
Hydrochloric Acid SCHEMBL359881 0.69
SCHEMBL8844520 0.69
Hydrochloric Acid SCHEMBL773202 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710428-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-25 EP disclosed
EP-4707276-A2 MALT1 MODULATORS AND USES THEREOF Rarefied Biosciences, Inc. (US) 2026-03-11 EP disclosed
EP-4499611-B1 MALT1 MODULATORS AND USES THEREOF RAREFIED BIOSCIENCES INC (US) 2026-02-18 EP disclosed
US-20250353820-A1 ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS NOVARTIS AG (CH) 2025-11-20 US disclosed
US-20250326738-A1 MALT1 Modulators and Uses Thereof RAREFIED BIOSCIENCES, INC. (US) 2025-10-23 US disclosed
US-12338220-B2 Antiviral pyrazolopiridinone compounds GILEAD SCIENCES, INC. (US) 2025-06-24 US disclosed
EP-4499611-A1 MALT1 MODULATORS AND USES THEREOF Rarefied Biosciences, Inc. (US) 2025-02-05 EP disclosed
CN-119032083-A MALT1 modulators and uses thereof 稀有生物科学股份有限公司 2024-11-26 CN disclosed
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-09-19 US disclosed
CN-112204009-B Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2024-05-07 CN disclosed
WO-2009105500-A1 COMPOUNDS THAT ARE ERK INHIBITORS SCHERING CORPORATION (US) 2009-08-27 WO disclosed
WO-2009105500-A1 COMPOUNDS THAT ARE ERK INHIBITORS SCHERING CORPORATION (US) 2009-08-27 WO disclosed
US-7429665-B2 Heteroaromatic quinoline compounds PFIZER INC (US) 2008-09-30 US disclosed
US-20080214607-A1 HETEROAROMATIC QUINOLINE COMPOUNDS PFIZER INC 2008-09-04 US disclosed
CN-101098866-A Heteroaromatic quinoline compounds and their use as pde10 inhibitors PFIZER (US) 2008-01-02 CN disclosed
EP-1841757-A2 HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS Pfizer Products Incorporated (US) 2007-10-10 EP disclosed
US-20060154931-A1 Heteroaromatic quinoline compounds PFIZER INC 2006-07-13 US disclosed
WO-2006072828-A2 HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PFIZER PRODUCTS INC. (US) 2006-07-13 WO disclosed
US-5612332-A INHIBITING PROTEIN GLYCOSYLATION ALTEON INC. (US) 1997-03-18 US disclosed
WO-1996040663-A1 DI- AND TRI-AMINOGUANIDINES AND THEIR USE TO INHIBIT THE ADVANCED GLYCOSYLATION OF PROTEINS ALTEON INC. (US) 1996-12-19 WO disclosed